Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273


Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.

Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, Iannacone M, Radovic-Moreno AF, Langer RS, Farokhzad OC, von Andrian UH, Johnston LP, Kishimoto TK.

Vaccine. 2014 May 19;32(24):2882-95. doi: 10.1016/j.vaccine.2014.02.027. Epub 2014 Mar 1.


TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Johnson TR, Rao S, Seder RA, Chen M, Graham BS.

Vaccine. 2009 May 18;27(23):3045-52. doi: 10.1016/j.vaccine.2009.03.026. Epub 2009 Apr 3.


TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.

McKay PF, King DF, Mann JF, Barinaga G, Carter D, Shattock RJ.

PLoS One. 2016 Feb 10;11(2):e0148984. doi: 10.1371/journal.pone.0148984. eCollection 2016.


Co-delivery of Dual Toll-Like Receptor Agonists and Antigen in Poly(Lactic-Co-Glycolic) Acid/Polyethylenimine Cationic Hybrid Nanoparticles Promote Efficient In Vivo Immune Responses.

Ebrahimian M, Hashemi M, Maleki M, Hashemitabar G, Abnous K, Ramezani M, Haghparast A.

Front Immunol. 2017 Sep 13;8:1077. doi: 10.3389/fimmu.2017.01077. eCollection 2017.


Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.

Dowling DJ, Scott EA, Scheid A, Bergelson I, Joshi S, Pietrasanta C, Brightman S, Sanchez-Schmitz G, Van Haren SD, Ninković J, Kats D, Guiducci C, de Titta A, Bonner DK, Hirosue S, Swartz MA, Hubbell JA, Levy O.

J Allergy Clin Immunol. 2017 Nov;140(5):1339-1350. doi: 10.1016/j.jaci.2016.12.985. Epub 2017 Mar 23.


TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.

Johnston D, Zaidi B, Bystryn JC.

Cancer Immunol Immunother. 2007 Aug;56(8):1133-41. Epub 2006 Dec 1.


Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.

Rostamian M, Niknam HM.

Mol Immunol. 2017 Nov;91:202-208. doi: 10.1016/j.molimm.2017.09.010. Epub 2017 Sep 30.


TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.

Hjelm BE, Kilbourne J, Herbst-Kralovetz MM.

Hum Vaccin Immunother. 2014;10(2):410-6. doi: 10.4161/hv.27147. Epub 2013 Nov 26.


Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.

Shima F, Uto T, Akagi T, Akashi M.

Bioconjug Chem. 2013 Jun 19;24(6):926-33. doi: 10.1021/bc300611b. Epub 2013 May 13.


An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM.

Clin Vaccine Immunol. 2010 Dec;17(12):1850-8. doi: 10.1128/CVI.00230-10. Epub 2010 Oct 20.


The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.

Vasilakos JP, Tomai MA.

Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208. Review.


Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.

Ebrahimian M, Hashemi M, Maleki M, Abnous K, Hashemitabar G, Ramezani M, Haghparast A.

Int J Pharm. 2016 Dec 30;515(1-2):708-720. doi: 10.1016/j.ijpharm.2016.10.065. Epub 2016 Oct 29.


Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.

Zhang WW, Matlashewski G.

Infect Immun. 2008 Aug;76(8):3777-83. doi: 10.1128/IAI.01527-07. Epub 2008 May 12.


Topical resiquimod promotes priming of CTL to parenteral antigens.

Chang BA, Cross JL, Najar HM, Dutz JP.

Vaccine. 2009 Sep 25;27(42):5791-9. doi: 10.1016/j.vaccine.2009.07.062. Epub 2009 Aug 4.


A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Gwinn WM, Johnson BT, Kirwan SM, Sobel AE, Abraham SN, Gunn MD, Staats HF.

Vaccine. 2013 Mar 1;31(11):1480-9. doi: 10.1016/j.vaccine.2013.01.012. Epub 2013 Jan 23.


TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.

Du J, Wu Z, Ren S, Wei Y, Gao M, Randolph GJ, Qu C.

Vaccine. 2010 Aug 31;28(38):6273-81. doi: 10.1016/j.vaccine.2010.06.117. Epub 2010 Jul 15.


Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.

Diwan M, Elamanchili P, Cao M, Samuel J.

Curr Drug Deliv. 2004 Oct;1(4):405-12.


Supplemental Content

Support Center